The company had issued 1 share of the new company for every 10 of the parent company. Nicholas Piramal will hold 18 per cent of new company and 82 per cent will be held by NPIL shareholders.
Nicholas Piramal also transfered Rs 95 crore of assets to the new company. PLSL is focused on four therapeutic areas
